Ikuo Sekine
About
Ikuo Sekine is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Ikuo Sekine has authored 228 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Oncology, 121 papers in Pulmonary and Respiratory Medicine and 52 papers in Molecular Biology. Recurrent topics in Ikuo Sekine's work include Lung Cancer Treatments and Mutations (100 papers), Lung Cancer Research Studies (73 papers) and Lung Cancer Diagnosis and Treatment (42 papers). Ikuo Sekine is often cited by papers focused on Lung Cancer Treatments and Mutations (100 papers), Lung Cancer Research Studies (73 papers) and Lung Cancer Diagnosis and Treatment (42 papers). Ikuo Sekine collaborates with scholars based in Japan, United States and United Kingdom. Ikuo Sekine's co-authors include Tomohide Tamura, Noboru Yamamoto, Hideo Kunitoh, Hiroshi Nokihara, Yuichiro Ohe, Nagahiro Saijo, Koji Tsuta, Kaoru Kubota, Seiichiro Yamamoto and Toshimi Takano and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
In The Last Decade
Ikuo Sekine
215 papers receiving 5.6k citations
Hit Papers
Peers
Ikuo Sekine
Kaoru Kubota Japan
Emilio Bria Italy
Hideo Kunitoh Japan
Philip Bonomi United States
Umberto Basso Italy
B. Milleron France
P. Kosmidis Greece
Romain Coriat France
Philipp A. Schnabel Germany
Hideo Saka Japan
Citations per year, relative to Ikuo Sekine Ikuo Sekine (= 1×)
peers
Kaoru Kubota
Countries citing papers authored by Ikuo Sekine
Since
Specialization
Citations
This map shows the geographic impact of Ikuo Sekine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ikuo Sekine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ikuo Sekine more than expected).
Fields of papers citing papers by Ikuo Sekine
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ikuo Sekine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ikuo Sekine. The network helps show where Ikuo Sekine may publish in the future.
Co-authorship network of co-authors of Ikuo Sekine
This figure shows the co-authorship network connecting the top 25 collaborators of Ikuo Sekine. A scholar is included among the top collaborators of Ikuo Sekine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ikuo Sekine. Ikuo Sekine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ohgami, Masahiro, et al.. (2024). Pharmacokinetic study of erlotinib in a pregnant woman with advanced non‐small cell lung cancer and observation of the effects on the child growth. British Journal of Clinical Pharmacology. 90(10). 2554–2561.
2.
Sekine, Ikuo. (2023). Clinical development of immune checkpoint inhibitors in Japan—the same goal, different paths. Japanese Journal of Clinical Oncology. 53(10). 873–874.
3.
Iida, Noriko, Kazuko Tajiri, Tomoko Ishizu, et al.. (2022). Echocardiography image quality of global longitudinal strain in cardio-oncology: a prospective real-world investigation. Journal of Echocardiography. 20(3). 159–165.
4.
Kanda, Shintaro, Hidehito Horinouchi, Yutaka Fujiwara, et al.. (2015). Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 89(3). 287–293.
5.
Kawamura, Kiyoko, Shinya Okamoto, Takao Morinaga, et al.. (2015). Replication-competent adenoviruses with the type 35-derived fiber-knob region achieve reactive oxygen species-dependent cytotoxicity and produce greater toxicity than those with the type 5-derived region in pancreatic carcinoma. APOPTOSIS. 20(12). 1587–1598.
6.
Sekine, Ikuo, Hiroaki Okamoto, Takeshi Horai, et al.. (2013). A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer. Clinical Lung Cancer. 15(2). 96–102.
7.
Horinouchi, Hidehito, Ikuo Sekine, Minako Sumi, et al.. (2012). Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: Carcinoembryonic antigen as a potential predictive factor. Cancer Science. 103(4). 756–759.
8.
Sekine, Ikuo, Minako Sumi, Yoshinori Ito, et al.. (2011). Phase I Study of Concurrent High-Dose Three-Dimensional Conformal Radiotherapy With Chemotherapy Using Cisplatin and Vinorelbine for Unresectable Stage III Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 82(2). 953–959.
9.
Furugen, Makoto, Ikuo Sekine, K. Tsuta, et al.. (2011). Combination Chemotherapy with Carboplatin and Paclitaxel for Advanced Thymic Cancer. Japanese Journal of Clinical Oncology. 41(8). 1013–1016.
10.
Sekine, Ikuo, Kaoru Kubota, Yosuke Tamura, et al.. (2010). Innovator and generic cisplatin formulations: Comparison of renal toxicity. Cancer Science. 102(1). 162–165.
11.
Sekine, Ikuo, Hiroshi Nokihara, Noboru Yamamoto, et al.. (2009). Comparative Chemotherapeutic Efficacy in Non-small Cell Lung Cancer Patients with Postoperative Recurrence and Stage IV Disease. Journal of Thoracic Oncology. 4(4). 518–521.
12.
Sekine, Ikuo, Y. Ichinose, Yutaka Nishiwaki, et al.. (2009). Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Annals of Oncology. 20(9). 1483–1488.
13.
Goto, Yasushi, Ikuo Sekine, Hiroshi Sekiguchi, et al.. (2009). Differences in the Quality of Information on the Internet about Lung Cancer between the United States and Japan. Journal of Thoracic Oncology. 4(7). 829–833.
14.
Goto, Yasushi, Ikuo Sekine, Kazuhiko Yamada, et al.. (2008). Influence of Previous Chemotherapy on the Efficacy of Subsequent Docetaxel Therapy in Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 3(4). 412–416.
15.
Yamamoto, Harukaze, Ikuo Sekine, Kazuhiko Yamada, et al.. (2008). Gender Differences in Treatment Outcomes among Patients with Non-Small Cell Lung Cancer Given a Combination of Carboplatin and Paclitaxel. Oncology. 75(3-4). 169–174.
16.
Sekine, Ikuo, Kazuhiko Yamada, Hiroshi Nokihara, et al.. (2007). Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity. Cancer Science. 98(9). 1408–1412.
17.
Sekine, Ikuo, Yukito Ichinose, Yutaka Nishiwaki, et al.. (2007). B3-01: A randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small-cell lung cancer. Journal of Thoracic Oncology. 2(8). S339–S340.
18.
Sekine, Ikuo, Hiroshi Nokihara, Minako Sumi, et al.. (2006). Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(8). 810–815.
19.
Ohe, Yuichiro, Naoki Ishizuka, Tomohide Tamura, et al.. (2003). Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Science. 94(8). 729–734.
20.
Sekine, Ikuo, Noboru Yamamoto, Hideo Kunitoh, et al.. (2002). Relationship between objective responses in phase I trialsand potential efficacy of non-specific cytotoxic investigational new drugs. Annals of Oncology. 13(8). 1300–1306.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kaoru Kubota Breakdown of academic impact, for papers by Emilio Bria Breakdown of academic impact, for papers by Hideo Kunitoh Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Umberto Basso Breakdown of academic impact, for papers by B. Milleron Breakdown of academic impact, for papers by P. Kosmidis Breakdown of academic impact, for papers by Romain Coriat Breakdown of academic impact, for papers by Philipp A. Schnabel Breakdown of academic impact, for papers by Hideo Saka